Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL ·

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat a type of esophageal cancer called esophageal squamous cell carcinoma. The researchers want to see if adding a treatment called high-dose-rate (HDR) brachytherapy—a targeted radiation therapy delivered inside the esophagus—can help prevent the cancer from coming back within a year. This treatment is given after patients have already received standard treatments, including external radiation, chemotherapy, and an immune-boosting medicine called nivolumab.

People who may be eligible for this trial are adults with locally advanced esophageal squamous cell carcinoma who have finished their initial treatments and are starting nivolumab. If you join, you will receive one or two sessions of HDR brachytherapy through a thin tube placed inside your esophagus, within three weeks of starting nivolumab. You will continue taking nivolumab and have regular check-ups, scans, and blood tests to see how well the treatment is working and to watch for any side effects. The trial is currently recruiting participants of all genders, and the main goals are to find out if this combined treatment is safe and if it helps keep the cancer from coming back.

Gender

ALL

Eligibility criteria